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Abstract
Use of prescription stimulants by normal healthy individuals to enhance cognition is said to be on the rise.
Who is using these medications for cognitive enhancement, and how prevalent is this practice? Do
prescription stimulants in fact enhance cognition for normal healthy people? We review the
epidemiological and cognitive neuroscience literatures in search of answers to these questions.
Epidemiological issues addressed include the prevalence of nonmedical stimulant use, user
demographics, methods by which users obtain prescription stimulants, and motivations for use. Cognitive
neuroscience issues addressed include the effects of prescription stimulants on learning and executive
function, as well as the task and individual variables associated with these effects. Little is known about
the prevalence of prescription stimulant use for cognitive enhancement outside of student populations.
Among college students, estimates of use vary widely but, taken together, suggest that the practice is
commonplace. The cognitive effects of stimulants on normal healthy people cannot yet be characterized
definitively, despite the volume of research that has been carried out on these issues. Published evidence
suggests that declarative memory can be improved by stimulants, with some evidence consistent with
enhanced consolidation of memories. Effects on the executive functions of working memory and
cognitive control are less reliable but have been found for at least some individuals on some tasks. In
closing, we enumerate the many outstanding questions that remain to be addressed by future research
and also identify obstacles facing this research.
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Are Prescription Stimulants “Smart Pills”?:
The Epidemiology and Cognitive Neuroscience of Prescription Stimulant Use by Normal
Healthy Individuals
M. Elizabeth Smith and
Department of Psychology, University of Pennsylvania
Martha J. Farah
Center for Neuroscience & Society, University of Pennsylvania

Abstract
Use of prescription stimulants by normal healthy individuals to enhance cognition is said to be on
the rise. Who is using these medications for cognitive enhancement, and how prevalent is this
practice? Do prescription stimulants in fact enhance cognition for normal healthy people? We
review the epidemiological and cognitive neuroscience literatures in search of answers to these
questions. Epidemiological issues addressed include the prevalence of nonmedical stimulant use,
user demographics, methods by which users obtain prescription stimulants, and motivations for
use. Cognitive neuroscience issues addressed include the effects of prescription stimulants on
learning and executive function, as well as the task and individual variables associated with these
effects. Little is known about the prevalence of prescription stimulant use for cognitive
enhancement outside of student populations. Among college students, estimates of use vary
widely but, taken together, suggest that the practice is commonplace. The cognitive effects of
stimulants on normal healthy people cannot yet be characterized definitively, despite the volume
of research that has been carried out on these issues. Published evidence suggests that declarative
memory can be improved by stimulants, with some evidence consistent with enhanced
consolidation of memories. Effects on the executive functions of working memory and cognitive
control are less reliable but have been found for at least some individuals on some tasks. In
closing, we enumerate the many outstanding questions that remain to be addressed by future
research and also identify obstacles facing this research.

Keywords
amphetamine; enhancement; neuroethics; psychopharmacology; stimulant
A “smart pill” is a drug that increases the cognitive ability of anyone taking it, whether the
user is cognitively impaired or normal. The Romanian neuroscientist Corneliu Giurgea is
often credited with first proposing, in the 1960s, that smart pills should be developed to
increase the intelligence of the general population (see Giurgea, 1984). He is quoted as
saying, “Man is not going to wait passively for millions of years before evolution offers him
a better brain” (Gazzaniga, 2005, p. 71). In their best-selling book, Smart Drugs and
Nutrients, Dean and Morgenthaler (1990) reviewed a large number of substances that have
been used by healthy individuals with the goal of increasing cognitive ability. These include
synthetic and natural products that affect neurotransmitter levels, neurogenesis, and blood

© 2011 American Psychological Association
Correspondence concerning this article should be addressed to Martha J. Farah, Center for Neuroscience & Society, University of
Pennsylvania, 3720 Walnut Street, Philadelphia, PA 19104. mfarah@psych.upenn.edu.

Smith and Farah

Page 2

flow to the brain. Although many of these substances have their adherents, none have
become widely used. Caffeine and nicotine may be exceptions to this generalization, as one
motivation among many for their use is cognitive enhancement (Julien, 2001).
Another class of substances with the potential to enhance cognition in normal healthy
individuals is the class of prescription stimulants used to treat attention-deficit/hyperactivity
disorder (ADHD). These include methylphenidate (MPH), best known as Ritalin or
Concerta, and amphetamine (AMP), most widely prescribed as mixed AMP salts consisting
primarily of dextroamphetamine (d-AMP), known by the trade name Adderall. These
medications have become familiar to the general public because of the growing rates of
diagnosis of ADHD children and adults (Froehlich et al., 2007; Sankaranarayanan, Puumala,
& Kratochvil, 2006) and the recognition that these medications are effective for treating
ADHD (MTA Cooperative Group, 1999; Swanson et al., 2008).
To judge from recent reports in the popular media, healthy people have also begun to use
MPH and AMPs for cognitive enhancement. Major daily newspapers such as The New York
Times, The LA Times, and The Wall Street Journal; magazines including Time, The
Economist, The New Yorker, and Vogue; and broadcast news organizations including the
BBC, CNN, and NPR have reported a trend toward growing use of prescription stimulants
by healthy people for the purpose of enhancing school or work performance.

Nature magazine conducted a poll asking its readers about their cognitive-enhancement
practices and their attitudes toward cognitive enhancement. Hundreds of college faculty and
other professionals responded, and approximately one fifth reported using drugs for
cognitive enhancement, with Ritalin being the most frequently named (Maher, 2008).
However, the nature of the sample—readers choosing to answer a poll on cognitive
enhancement—is not representative of the academic or general population, making the
results of the poll difficult to interpret. By analogy, a poll on Vermont vacations, asking
whether people vacation in Vermont, what they think about Vermont, and what they do if
and when they visit, would undoubtedly not yield an accurate estimate of the fraction of the
population that takes its vacations in Vermont.
The ethics of cognitive enhancement have been extensively debated in the academic
literature (e.g., Bostrom & Sandberg, 2009; Farah et al., 2004; Greely et al., 2008; Mehlman,
2004; Sahakian & Morein-Zamir, 2007). We do not attempt to review this aspect of the
problem here. Rather, we attempt to provide a firmer empirical basis for these discussions.
Despite the widespread interest in the topic and its growing public health implications, there
remains much researchers do not know about the use of prescription stimulants for cognitive
enhancement.
Among the questions to be addressed in the present article are, How widespread is the use of
prescription stimulants for cognitive enhancement? Who uses them, for what specific
purposes? Given that nonmedical use of these substances is illegal, how are they obtained?
Furthermore, do these substances actually enhance cognition? If so, what aspects of
cognition do they enhance? Is everyone able to be enhanced, or are some groups of healthy
individuals helped by these drugs and others not? The goal of this article is to address these
questions by reviewing and synthesizing findings from the existing scientific literature. We
begin with a brief overview of the psychopharmacology of the two most commonly used
prescription stimulants.

History and Psychopharmacology of Amphetamine and Methylphenidate
AMP was first investigated as an asthma medication in the 1920s, but its psychological
effects were soon noticed. These included increased feelings of energy, positive mood, and
Psychol Bull. Author manuscript; available in PMC 2013 March 08.
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prolonged physical endurance and mental concentration. These effects have been exploited
in a variety of medical and nonmedical applications in the years since they were discovered,
including to treat depression, to enhance alertness in military personnel, and to provide a
competitive edge in athletic competition (Rasmussen, 2008). Today, AMP remains a widely
used and effective treatment for ADHD (Wilens, 2006).
MPH was developed more recently and marketed primarily for ADHD, although it is
sometimes prescribed off label or used nonmedically to increase alertness, energy, or
concentration in conditions other than ADHD. Both MPH and AMP are on the list of
substances banned from sports competitions by the World Anti-Doping Agency (Docherty,
2008). Both also have the potential for abuse and dependence, which detracts from their
usefulness and is the reason for their classification as Schedule II controlled substances.
Although the risk of developing dependence on these drugs is believed to be low for
individuals taking them for ADHD, the Schedule II classification indicates that these drugs
have a high potential for abuse and that abuse may lead to severe dependence.
The beneficial effects as well as the potentially serious side effects of these drugs can be
understood in terms of their effects on the catecholamine neurotransmitters dopamine and
norepinephrine (Wilens, 2006). These neurotransmitters play an important role in cognition,
affecting the cortical and subcortical systems that enable people to focus and flexibly deploy
attention (Robbins & Arnsten, 2009). In addition, the brain’s reward centers are innervated
by dopamine neurons, accounting for the pleasurable feelings engendered by these
stimulants (Robbins & Everett, 1996).
The therapeutic effect of AMP and MPH in ADHD is consistent with the finding of
abnormalities in the catecholamine system in individuals with ADHD (e.g., Volkow et al.,
2007). Both AMP and MPH exert their effects on cognition primarily by increasing levels of
catecholamines in prefrontal cortex and the cortical and subcortical regions projecting to it,
and this mechanism is responsible for improving cognition and behavior in ADHD (Pliszka,
2005; Wilens, 2006).
AMP and MPH increase catecholamine activity in different ways. MPH primarily inhibits
the reuptake of dopamine by pre-synaptic neurons, thus leaving more dopamine in the
synapse and available for interacting with the receptors of the postsynaptic neuron. AMP
also affects reuptake, as well as increasing the rate at which neurotransmitter is released
from presynaptic neurons (Wilens, 2006). These effects are manifest in the attention systems
of the brain, as already mentioned, and in a variety of other systems that depend on
catecholaminergic transmission as well, giving rise to other physical and psychological
effects. Physical effects include activation of the sympathetic nervous system (i.e., a fightor-flight response), producing increased heart rate and blood pressure. Psychological effects
are mediated by activation of the nucleus accumbens, ventral striatum, and other parts of the
brain’s reward system, producing feelings of pleasure and the potential for dependence.

Are Prescription Stimulants Being Used as Smart Pills?
Large U.S. Government Surveys
Most epidemiological research on nonmedical stimulant use has been focused on issues
relevant to traditional problems of drug abuse and addiction, and so, stimulant use for
cognitive enhancement is not generally distinguished from use for other purposes, such as
staying awake or getting high. As Boyd and McCabe (2008) pointed out, the large national
surveys of nonmedical prescription drug use have so far failed to distinguish the ways and
reasons that people use the drugs, and this is certainly true where prescription stimulants are
concerned. The largest survey to investigate prescription stimulant use in a nationally
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representative sample of Americans, the National Survey on Drug Use and Health
(NSDUH), phrases the question about nonmedical use as follows: “Have you ever, even
once, used any of these stimulants when they were not prescribed for you or that you took
only for the experience or feeling they caused?” (Snodgrass & LeBaron 2007). This
phrasing does not strictly exclude use for cognitive enhancement, but it emphasizes the
noncognitive effects of the drugs. In 2008, the NSDUH found a prevalence of 8.5% for
lifetime nonmedical stimulant use by Americans over the age of 12 years and a prevalence
of 12.3% for Americans between 21 and 25 (Substance Abuse and Mental Health Services
Administration, 2009).
In addition, large national surveys, including the NSDUH, have generally classified
prescription stimulants with other stimulants including street drugs such as
methamphetamine. For example, since 1975, the National Institute on Drug Abuse–
sponsored Monitoring the Future (MTF) survey has gathered data on drug use by young
people in the United States (Johnston, O’Malley, Bachman, & Schulenberg, 2009a, 2009b).
Originally, MTF grouped prescription stimulants under a broader class of stimulants so that
respondents were asked specifically about MPH only after they had indicated use of some
drug in the category of AMPs. As rates of MPH prescriptions increased and anecdotal
reports of nonmedical use grew, the 2001 version of the survey was changed to include a
separate standalone question about MPH use. This resulted in more than a doubling of
estimated annual use among 12th graders, from 2.4% to 5.1%. More recent data from the
MTF suggests Ritalin use has declined (3.4% in 2008). However, this may still
underestimate use of MPH, as the question refers specifically to Ritalin and does not include
other brand names such as Concerta (an extended release formulation of MPH).
Turning to analyses related specifically to the drugs that are the subject of this article,
reanalysis of the 2002 NSDUH data by Kroutil and colleagues (2006) found past-year
nonmedical use of stimulants other than methamphetamine by 2% of individuals between
the ages of 18 and 25 and by 0.3% of individuals 26 years of age and older. For ADHD
medications in particular, these rates were 1.3% and 0.1%, respectively. Finally, Novak,
Kroutil, Williams, and Van Brunt (2007) surveyed a sample of over four thousand
individuals from the Harris Poll Online Panel and found that 4.3% of those surveyed
between the ages of 18 and 25 had used prescription stimulants nonmedically in the past
year, compared with only 1.3% between the ages of 26 and 49.
Surveys of Student Nonmedical Stimulant Use
We reviewed recent studies concerning prescription stimulant use specifically among
students in the United States and Canada, using the method illustrated in Figure 1. Although
less informative about the general population, these studies included questions about
students’ specific reasons for using the drugs, as well as frequency of use and means of
obtaining them. These studies typically found rates of use greater than those reported by the
nationwide NSDUH or the MTF surveys. This probably reflects a true difference in rates of
usage among the different populations. In support of that conclusion, the NSDUH data for
college age Americans showed that college students were considerably more likely than
nonstudents of the same age to use prescription stimulants nonmedically (odds ratio: 2.76;
Herman-Stahl, Krebs, Kroutil, & Heller, 2007).
Table 1 shows all of the studies of middle school, secondary school, and college students
that we identified. As indicated in the table, the studies are heterogeneous, with varying
populations sampled, sample sizes, and year of data collection, and they focused on different
subsets of the epidemiological questions addressed here, including prevalence and frequency
of use, motivations for use, and method of obtaining the medication.
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Prevalence and frequency of use—Four of the studies focused on middle and high
school students, with varied results. Boyd, McCabe, Cranford, and Young (2006) found a
2.3% lifetime prevalence of nonmedical stimulant use in their sample, and McCabe, Teter,
and Boyd (2004) found a 4.1% lifetime prevalence in public school students from a single
American public school district. Poulin (2001) found an 8.5% past-year prevalence in public
school students from four provinces in the Atlantic region of Canada. A more recent study
of the same provinces found a 6.6% and 8.7% past-year prevalence for MPH and AMP use,
respectively (Poulin, 2007).
By the end of 2009, at least 25 studies reported surveys of college students’ rates of
nonmedical stimulant use. Of the studies using relatively smaller samples, prevalence was,
in chronological order, 16.6% (lifetime; Babcock & Byrne, 2000), 35.3% (past year; Low &
Gendaszek, 2002), 13.7% (lifetime; Hall, Irwin, Bowman, Frankenberger, & Jewett, 2005),
9.2% (lifetime; Carroll, McLaughlin, & Blake, 2006), and 55% (lifetime, fraternity students
only; DeSantis, Noar, & Web, 2009). Of the studies using samples of more than a thousand
students, somewhat lower rates of nonmedical stimulant use were found, although the range
extends into the same high rates as the small studies: 2.5% (past year, Ritalin only; Teter,
McCabe, Boyd, & Guthrie, 2003), 5.4% (past year; McCabe & Boyd, 2005), 4.1% (past
year; McCabe, Knight, Teter, & Wechsler, 2005), 11.2% (past year; Shillington, Reed,
Lange, Clapp, & Henry, 2006), 5.9% (past year; Teter, McCabe, LaGrange, Cranford, &
Boyd, 2006), 16.2% (lifetime; White, Becker-Blease, & Grace-Bishop, 2006), 1.7% (past
month; Kaloyanides, McCabe, Cranford, & Teter, 2007), 10.8% (past year; Arria, O’Grady,
Caldeira, Vincent, & Wish, 2008); 5.3% (MPH only, lifetime; Du-Pont, Coleman, Bucher,
& Wilford, 2008); 34% (lifetime; DeSantis, Webb, & Noar, 2008), 8.9% (lifetime; Rabiner
et al., 2009), and 7.5% (past month; Weyandt et al., 2009).
The question of how much nonmedical use of stimulants occurs on college campuses is only
partly answered by the proportion of students using the drugs in this way. The other part of
the answer is how frequently they are used by those students. Three studies addressed this
issue. Low and Gendaszek (2002) found a high past-year rate of 35.3%, but only 10% and
8% of this population used monthly and weekly, respectively. White et al. (2006) found a
larger percentage used frequently: 15.5% using two to three times per week and 33.9% using
two to three times per month. Teter et al. (2006) found that most nonmedical users take
prescription stimulants sporadically, with well over half using five or fewer times and nearly
40% using only once or twice in their lives. DeSantis et al. (2008) offered qualitative
evidence on the issue, reporting that students often turned to stimulants at exam time only,
particularly when under pressure to study for multiple exams at the same time. Thus, there
appears to be wide variation in the regularity of stimulant use, with the most common
pattern appearing to be infrequent use.
Overall, the studies listed in Table 1 vary in ways that make it difficult to draw precise
quantitative conclusions from them, including their definitions of nonmedical use, methods
of sampling, and demographic characteristics of the samples. For example, some studies
defined nonmedical use in a way that excluded anyone for whom a drug was prescribed,
regardless of how and why they used it (Carroll et al., 2006; DeSantis et al., 2008, 2009;
Kaloyanides et al., 2007; Low & Gendaszek, 2002; McCabe & Boyd, 2005; McCabe et al.,
2004; Rabiner et al., 2009; Shillington et al., 2006; Teter et al., 2003, 2006; Weyandt et al.,
2009), whereas others focused on the intent of the user and counted any use for nonmedical
purposes as nonmedical use, even if the user had a prescription (Arria et al., 2008; Babcock
& Byrne, 2000; Boyd et al., 2006; Hall et al., 2005; Herman-Stahl et al., 2007; Poulin, 2001,
2007; White et al., 2006), and one did not specify its definition (Barrett, Darredeau, Bordy,
& Pihl, 2005). Some studies sampled multiple institutions (DuPont et al., 2008; McCabe &
Boyd, 2005; Poulin, 2001, 2007), some sampled only one (Babcock & Byrne, 2000; Barrett
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et al., 2005; Boyd et al., 2006; Carroll et al., 2006; Hall et al., 2005; Kaloyanides et al.,
2007; McCabe & Boyd, 2005; McCabe et al., 2004; Shillington et al., 2006; Teter et al.,
2003, 2006; White et al., 2006), and some drew their subjects primarily from classes in a
single department at a single institution (DeSantis et al., 2008, 2009; Low & Gendaszek,
2002). With few exceptions, the samples were all drawn from restricted geographical areas.
Some had relatively high rates of response (e.g., 93.8%; Low & Gendaszek 2002) and some
had low rates (e.g., 10%; Judson & Langdon, 2009), the latter raising questions about
sample representativeness for even the specific population of students from a given region or
institution.
In the largest nationwide study, McCabe et al. (2005) sampled 10,904 students at 119 public
and private colleges and universities across the United States, providing the best estimate of
prevalence among American college students in 2001, when the data were collected. This
survey found 6.9% lifetime, 4.1% past-year, and 2.1% past-month nonmedical use of a
prescription stimulant. It also found that prevalence depended strongly on student and school
characteristics, consistent with the variability noted among the results of single-school
studies. The strongest predictors of past-year nonmedical stimulant use by college students
were admissions criteria (competitive and most competitive more likely than less
competitive), fraternity/sorority membership (members more likely than nonmembers), and
gender (males more likely than females).
Access—As already mentioned, AMPs and MPH are classified by the U.S. Food and Drug
Administration (FDA) as Schedule II substances, which means that buying or selling them is
a felony offense. This raises the question of how the drugs are obtained by students for
nonmedical use. Several studies addressed this question and yielded reasonably consistent
answers.
The majority of nonmedical users reported obtaining prescription stimulants from a peer
with a prescription (Barrett et al., 2005; Carroll et al., 2006; DeSantis et al., 2008, 2009;
DuPont et al., 2008; McCabe & Boyd, 2005; Novak et al., 2007; Rabiner et al., 2009; White
et al., 2006). Consistent with nonmedical user reports, McCabe, Teter, and Boyd (2006)
found 54% of prescribed college students had been approached to divert (sell, exchange, or
give) their medication. Studies of secondary school students supported a similar conclusion
(McCabe et al., 2004; Poulin, 2001, 2007). In Poulin’s (2007) sample, 26% of students with
prescribed stimulants reported giving or selling some of their medication to other students in
the past month. She also found that the number of students in a class with medically
prescribed stimulants was predictive of the prevalence of nonmedical stimulant use in the
class (Poulin, 2001). In McCabe et al.’s (2004) middle and high school sample, 23% of
students with prescriptions reported being asked to sell or trade or give away their pills over
their lifetime.
Student motivations for nonmedical use of prescription stimulants—How much
of the nonmedical use of prescription stimulants documented by these studies was for
cognitive enhancement? Prescription stimulants could be used for purposes other than
cognitive enhancement, including for feelings of euphoria or energy, to stay awake, or to
curb appetite. Were they being used by students as smart pills or as “fun pills,” “awake
pills,” or “diet pills”? Of course, some of these categories are not entirely distinct. For
example, by increasing the wakefulness of a sleep-deprived person or by lifting the mood or
boosting the motivation of an apathetic person, stimulants are likely to have the secondary
effect of improving cognitive performance. Whether and when such effects should be
classified as cognitive enhancement is a question to which different answers are possible,
and none of the studies reviewed here presupposed an answer. Instead, they show how the
respondents themselves classified their reasons for nonmedical stimulant use.
Psychol Bull. Author manuscript; available in PMC 2013 March 08.
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A total of 14 studies surveyed reasons for using prescription stimulants nonmedically, all but
one study confined to student respondents. The most common reasons were related to
cognitive enhancement. Different studies worded the multiple-choice alternatives
differently, but all of the following appeared among the top reasons for using the drugs:
“concentration” or “attention” (Boyd et al., 2006; DeSantis et al., 2008, 2009; Rabiner et al.,
2009; Teter et al., 2003, 2006; Teter, McCabe, Cranford, Boyd, & Guthrie, 2005; White et
al., 2006); “help memorize,” “study,” “study habits,” or “academic assignments” (Arria et
al., 2008; Barrett et al., 2005; Boyd et al., 2006; DeSantis et al., 2008, 2009; DuPont et al.,
2008; Low & Gendaszek, 2002; Rabiner et al., 2009; Teter et al., 2005, 2006; White et al.,
2006); “grades” or “intellectual performance” (Low & Gendaszek, 2002; White et al., 2006);
“before tests” or “finals week” (Hall et al., 2005); “alertness” (Boyd et al., 2006; Hall et al.,
2005; Teter et al., 2003, 2005, 2006); or “performance” (Novak et al., 2007). However,
every survey found other motives mentioned as well. The pills were also taken to “stay
awake,” “get high,” “be able to drink and party longer without feeling drunk,” “lose
weight,” “experiment,” and for “recreational purposes.”

Do Prescription Stimulants Work as Smart Pills?
The surveys just reviewed indicate that many healthy, normal students use prescription
stimulants to enhance their cognitive performance, based in part on the belief that stimulants
enhance cognitive abilities such as attention and memorization. Of course, it is possible that
these users are mistaken. One possibility is that the perceived cognitive benefits are placebo
effects. Another is that the drugs alter students’ perceptions of the amount or quality of work
accomplished, rather than affecting the work itself (Hurst, Weidner, & Radlow, 1967). A
third possibility is that stimulants enhance energy, wakefulness, or motivation, which
improves the quality and quantity of work that students can produce with a given,
unchanged, level of cognitive ability. To determine whether these drugs enhance cognition
in normal individuals, their effects on cognitive task performance must be assessed in
relation to placebo in a masked study design.
A number of different laboratory studies have assessed the acute effect of prescription
stimulants on the cognition of normal adults. In the next four sections, we review this
literature, with the goal of answering the following questions: First, do MPH (e.g., Ritalin)
and d-AMP (by itself or as the main ingredient in Adderall) improve cognitive performance
relative to placebo in normal healthy adults? Second, which cognitive systems are affected
by these drugs? Third, how do the effects of the drugs depend on the individual using them?
Accordingly, we searched the literature for studies in which MPH or d-AMP was
administered orally to nonelderly adults in a placebo-controlled design. Some of the studies
compared the effects of multiple drugs, in which case we report only the results of
stimulant–placebo comparisons; some of the studies compared the effects of stimulants on a
patient group and on normal control subjects, in which case we report only the results for
control subjects. The studies varied in many other ways, including the types of tasks used,
the specific drug used, the way in which dosage was determined (fixed dose or weightdependent dose), sample size, and subject characteristics (e.g., age, college sample or not,
gender). Our approach to the classic splitting versus lumping dilemma has been to take a
moderate lumping approach. We group studies according to the general type of cognitive
process studied and, within that grouping, the type of task. The drug and dose are reported,
as well as sample characteristics, but in the absence of pronounced effects of these factors,
we do not attempt to make generalizations about them.
We included studies of the effects of these drugs on cognitive processes including learning,
memory, and a variety of executive functions, including working memory and cognitive
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control. These studies are listed in Table 2, along with each study’s sample size, gender, age
and tasks administered. Given our focus on cognition enhancement, we excluded studies
whose measures were confined to perceptual or motor abilities. Studies of attention are
included when the term attention refers to an executive function but not when it refers to the
kind of perceptual process taxed by, for example, visual search or dichotic listening or when
it refers to a simple vigilance task. Vigilance may affect cognitive performance, especially
under conditions of fatigue or boredom, but a more vigilant person is not generally thought
of as a smarter person, and therefore, vigilance is outside of the focus of the present review.
The search and selection process is summarized in Figure 2.
For the sake of organizing the review, we have divided the literature according to the
general type of cognitive process being studied, with sections devoted to learning and to
various kinds of executive function. Executive function is a broad and, some might say,
vague concept that encompasses the processes by which individual perceptual, motoric, and
mnemonic abilities are coordinated to enable appropriate, flexible task performance,
especially in the face of distracting stimuli or alternative competing responses. Two major
aspects of executive function are working memory and cognitive control, responsible for the
maintenance of information in a short-term active state for guiding task performance and
responsible for inhibition of irrelevant information or responses, respectively. A large
enough literature exists on the effects of stimulants on these two executive abilities that
separate sections are devoted to each. In addition, a final section includes studies of
miscellaneous executive abilities including planning, fluency, and reasoning that have also
been the subjects of published studies.
Because executive functions tend to work in concert with one another, these three categories
are somewhat overlapping. For example, tasks that require working memory also require a
degree of cognitive control to prevent current stimuli from interfering with the contents of
working memory, and tasks that require planning, fluency, and reasoning require working
memory to hold the task goals in mind. The assignment of studies to sections was based on
best fit, according to the aspects of executive function most heavily taxed by the task, rather
than exclusive category membership. Within each section, studies are further grouped
according to the type of task and specific type of learning, working memory, cognitive
control, or other executive function being assessed.
The question of whether stimulants are smart pills in a pragmatic sense cannot be answered
solely by consideration of the statistical significance of the difference between stimulant and
placebo. A drug with tiny effects, even if statistically significant, would not be a useful
cognitive enhancer for most purposes. We therefore report Cohen’s d effect size measure for
published studies that provide either means and standard deviations or relevant F or t
statistics (Thalheimer & Cook, 2002). More generally, with most sample sizes in the range
of a dozen to a few dozen, small effects would not reliably be found.
Do Prescription Stimulants Enhance Learning?
Most people would describe school as a place where they go to learn, so learning is an
especially relevant cognitive process for students to enhance. Even outside of school,
however, learning plays a role in most activities, and the ability to enhance the retention of
information would be of value in many different occupational and recreational contexts.
Table 3 lists the results of 24 tasks from 22 articles on the effects of d-AMP or MPH on
learning, assessed by a variety of declarative and nondeclarative memory tasks. Results for
the 24 tasks are evenly split between enhanced learning and null results, but they yield a
clearer pattern when the nature of the learning task and the retention interval are taken into
account. In general, with single exposures of verbal material, no benefits are seen
Psychol Bull. Author manuscript; available in PMC 2013 March 08.
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immediately following learning, but later recall and recognition are enhanced. Of the six
articles reporting on memory performance (Camp-Bruno & Herting, 1994; Fleming,
Bigelow, Weinberger, & Goldberg, 1995; Rapoport, Busbaum, & Weingartner, 1980;
Soetens, D’Hooge, & Hueting, 1993; Unrug, Coenen, & van Luijtelaar, 1997; Zeeuws &
Soetens 2007), encompassing eight separate experiments, only one of the experiments
yielded significant memory enhancement at short delays (Rapoport et al., 1980). In contrast,
retention was reliably enhanced by d-AMP when subjects were tested after longer delays,
with recall improved after 1 hr through 1 week (Soetens, Casaer, D’Hooge, & Hueting,
1995; Soetens et al., 1993; Zeeuws & Soetens, 2007). Recognition improved after 1 week in
one study (Soetens et al., 1995), while another found recognition improved after 2 hr
(Mintzer & Griffiths, 2007). The one long-term memory study to examine the effects of
MPH found a borderline-significant reduction in errors when subjects answered questions
about a story (accompanied by slides) presented 1 week before (Brignell, Rosenthal, &
Curran, 2007).
Enhanced learning was also observed in two studies that involved multiple repeated
encoding opportunities. Camp-Bruno and Herting (1994) found MPH enhanced summed
recall in the Buschke Selective Reminding Test (Buschke, 1973; Buschke & Fuld, 1974)
when 1-hr and 2-hr delays were combined, although individually only the 2-hr delay
approached significance. Likewise, de Wit, Enggasser, and Richards (2002) found no effect
of d-AMP on the Hopkins Verbal Learning Test (Brandt, 1991) after a 25-min delay. Willett
(1962) tested rote learning of nonsense syllables with repeated presentations, and his results
indicate that d-AMP decreased the number of trials needed to reach criterion.
In paired-associates learning, subjects are presented with pairs of stimuli and must learn to
recall the second item of the pair when presented with the first. For these tasks, as with tasks
involving memory for individual items, there is a trend for stimulants to enhance
performance with longer delays. For immediate measures of learning, no effects of d-AMP
or MPH were observed by Brumaghim and Klorman (1998); Fleming et al. (1995); Hurst,
Radlow, and Weidner (1968); or Strauss et al. (1984). However, when Hurst et al.’s subjects
were tested a week later, they recalled more if their initial learning had been carried out with
d-AMP than with placebo. Weitzner (1965) assessed paired-associates learning with an
immediate cued-recall test and found facilitation when the associate word was semantically
related to the cue, provided it was not also related to other cue words. Finally, Burns, House,
French, and Miller (1967) found a borderline-significant impairment of performance with dAMP on a nonverbal associative learning task.
The information learned in the tasks reviewed so far was explicit, declarative, and consistent
within each experiment. In contrast, probabilistic and procedural learning tasks require the
subject to gradually extract a regularity in the associations among stimuli from multiple
presentations in which the correct associations are only presented some of the time, with
incorrect associations also presented. Findings are mixed in these tasks. Breitenstein and
colleagues (2004, 2006) showed subjects drawings of common objects accompanied by
nonsense word sounds in training sessions that extended over multiple days. They found
faster learning of the to-be-learned, higher probability pairings between sessions (consistent
with enhanced retention over longer delays). Breitenstein et al. (2004) found that this
enhancement remained a year later. Schlösser et al. (2009) tested subjects’ probabilistic
learning ability in the context of a functional magnetic resonance imaging (fMRI) study,
comparing performance and brain activation with MPH and placebo. MPH did not affect
learning performance as measured by accuracy. Although subjects were overall faster in
responding on MPH, this difference was independent of the difficulty of the learning task,
and the authors accordingly attributed it to response processes rather than learning.
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Two additional studies assessed the effects of d-AMP on visual–motor sequence learning, a
form of nondeclarative, procedural learning, and found no effect (Kumari et al., 1997;
Makris, Rush, Frederich, Taylor, & Kelly, 2007). In a related experimental paradigm, Ward,
Kelly, Foltin, and Fischman (1997) assessed the effect of d-AMP on the learning of motor
sequences from immediate feedback and also failed to find an effect.
A provisional conclusion about the effects of stimulants on learning is that they do help with
the consolidation of declarative learning, with effect sizes varying widely from small to
large depending on the task and individual study. Indeed, as a practical matter, stimulants
may be more helpful than many of the laboratory tasks indicate, given the apparent
dependence of enhancement on length of delay before testing. Although, as a matter of
convenience, experimenters tend to test memory for learned material soon after the learning,
this method has not generally demonstrated stimulant-enhanced learning. However, when
longer periods intervene between learning and test, a more robust enhancement effect can be
seen. Note that the persistence of the enhancement effect well past the time of drug action
implies that state-dependent learning is not responsible. In general, long-term effects on
learning are of greater practical value to people. Even students cramming for exams need to
retain information for more than an hour or two. We therefore conclude that stimulant
medication does enhance learning in ways that may be useful in the real world.
Do Prescription Stimulants Enhance Working Memory?
In contrast to the types of memory discussed in the previous section, which are long-lasting
and formed as a result of learning, working memory is a temporary store of information.
Working memory has been studied extensively by cognitive psychologists and cognitive
neuroscientists because of its role in executive function. It has been likened to an internal
scratch pad; by holding information in working memory, one keeps it available to consult
and manipulate in the service of performing tasks as diverse as parsing a sentence and
planning a route through the environment. Presumably for this reason, working memory
ability correlates with measures of general intelligence (Friedman et al., 2006). The
possibility of enhancing working memory ability is therefore of potential real-world interest.
Many laboratory tasks have been developed to study working memory, each of which taxes
to varying degrees aspects such as the overall capacity of working memory, its persistence
over time, and its resistance to interference either from task-irrelevant stimuli or among the
items to be retained in working memory (i.e., cross-talk). Tasks also vary in the types of
information to be retained in working memory, for example, verbal or spatial information.
The question of which of these task differences correspond to differences between distinct
working memory systems and which correspond to different ways of using a single
underlying system is a matter of debate (e.g., D’Esposito, Postle, & Rypma, 2000; Owen,
2000). For the present purpose, we ignore this question and simply ask, Do MPH and dAMP affect performance in the wide array of tasks that have been taken to operationalize
working memory? If the literature does not yield a unanimous answer to this question, then
what factors might be critical in determining whether stimulant effects are manifest?
Table 4 lists the results of 27 tasks from 23 articles on the effects of d-AMP or MPH on
working memory. The oldest and most commonly used type of working memory task in this
literature is the Sternberg short-term memory scanning paradigm (Sternberg, 1966), in
which subjects hold a set of items (typically letters or numbers) in working memory and are
then presented with probe items, to which they must respond “yes” (in the set) or “no” (not
in the set). The size of the set, and hence the working memory demand, is sometimes varied,
and the set itself may be varied from trial to trial to maximize working memory demands or
may remain fixed over a block of trials. Taken together, the studies that have used a version
of this task to test the effects of MPH and d-AMP on working memory have found mixed
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and somewhat ambiguous results. No pattern is apparent concerning the specific version of
the task or the specific drug. Four studies found no effect (Callaway, 1983; Kennedy,
Odenheimer, Baltzley, Dunlap, & Wood, 1990; Mintzer & Griffiths, 2007; Tipper et al.,
2005), three found faster responses with the drugs (Fitzpatrick, Klorman, Brumaghim, &
Keefover, 1988; Ward et al., 1997; D. E. Wilson et al., 1971), and one found higher
accuracy in some testing sessions at some dosages, but no main effect of drug (Makris et al.,
2007). The meaningfulness of the increased speed of responding is uncertain, given that it
could reflect speeding of general response processes rather than working memory–related
processes. Aspects of the results of two studies suggest that the effects are likely due to
processes other than working memory: D. E. Wilson et al. (1971) reported comparable
speeding in a simple task without working memory demands, and Tipper et al. (2005)
reported comparable speeding across set sizes.
Another common working memory task is the n-back task, which requires the subject to
view a series of items (usually letters) and decide whether the current item is identical to the
one presented n items back. This task taxes working memory because the previous items
must be held in working memory to be compared with the current item. The easiest version
of this is a 1-back task, which is also called a double continuous performance task (CPT)
because the subject is continuously monitoring for a repeat or double. Three studies
examined the effects of MPH on working memory ability as measured by the 1-back task,
and all found enhancement of performance in the form of reduced errors of omission
(Cooper et al., 2005; Klorman et al., 1984; Strauss et al., 1984). Fleming et al. (1995) tested
the effects of d-AMP on a 5-min CPT and found a decrease in reaction time, but did not
specify which version of the CPT was used.
The data from 2-back and 3-back tasks are more complex. Three studies examined
performance in these more challenging tasks and found no effect of d-AMP on average
performance (Mattay et al., 2000, 2003; Mintzer & Griffiths, 2007). However, in at least two
of the studies, the overall null result reflected a mixture of reliably enhancing and impairing
effects. Mattay et al. (2000) examined the performance of subjects with better and worse
working memory capacity separately and found that subjects whose performance on placebo
was low performed better on d-AMP, whereas subjects whose performance on placebo was
high were unaffected by d-AMP on the 2-back and impaired on the 3-back tasks. Mattay et
al. (2003) replicated this general pattern of data with subjects divided according to genotype.
The specific gene of interest codes for the production of Catechol-O-methyltransferase
(COMT), an enzyme that breaks down dopamine and norepinephrine. A common
polymorphism determines the activity of the enzyme, with a substitution of methionine for
valine at Codon 158 resulting in a less active form of COMT. The met allele is thus
associated with less breakdown of dopamine and hence higher levels of synaptic dopamine
than the val allele. Mattay et al. (2003) found that subjects who were homozygous for the
val allele were able to perform the n-back faster with d-AMP; those homozygous for met
were not helped by the drug and became significantly less accurate in the 3-back condition
with d-AMP. In the case of the third study finding no overall effect, analyses of individual
differences were not reported (Mintzer & Griffiths, 2007).
A related task is the B–X version of the CPT, in which subjects must respond when an X
appears only if it was preceded by a B. As in the 1-back task, the subject must retain the
previous trial’s letter in working memory because it determines the subject’s response to the
current letter. In this case, when the current letter is an X, then the subject should respond
only if the previous letter was a B. Two studies examined stimulant effects in this task.
Rapoport et al. (1980) found that d-AMP reduced errors of omission in the longer of two test
sessions, and Klorman et al. (1984) found that MPH reduced errors of omission and
response time.

Psychol Bull. Author manuscript; available in PMC 2013 March 08.

Smith and Farah

Page 12

Another classic approach to the assessment of working memory is the span task, in which a
series of items is presented to the subject for repetition, transcription, or recognition. The
longest series that can be reproduced accurately is called the forward span and is a measure
of working memory capacity. The ability to reproduce the series in reverse order is tested in
backward span tasks and is a more stringent test of working memory capacity and perhaps
other working memory functions as well. The digit span task from the Wechsler (1981) IQ
test was used in four studies of stimulant effects on working memory. One study showed
that d-AMP increased digit span (de Wit et al., 2002), and three found no effects of d-AMP
or MPH (Oken, Kishiyama, & Salinsky, 1995; Schmedtje, Oman, Letz, & Baker, 1988;
Silber, Croft, Papafotiou, & Stough, 2006). A spatial span task, in which subjects must
retain and reproduce the order in which boxes in a scattered spatial arrangement change
color, was used by Elliott et al. (1997) to assess the effects of MPH on working memory.
For subjects in the group receiving placebo first, MPH increased spatial span. However, for
the subjects who received MPH first, there was a nonsignificant opposite trend. The group
difference in drug effect is not easily explained. The authors noted that the subjects in the
first group performed at an overall lower level, and so, this may be another manifestation of
the trend for a larger enhancement effect for less able subjects.
Several studies have assessed the effect of MPH and d-AMP on tasks tapping various other
aspects of spatial working memory. Three used the spatial working memory task from the
CANTAB battery of neuropsychological tests (Sahakian & Owen, 1992). In this task,
subjects search for a target at different locations on a screen. Subjects are told that locations
containing a target in previous trials will not contain a target in future trials. Efficient
performance therefore requires remembering and avoiding these locations in addition to
remembering and avoiding locations already searched within a trial. Mehta et al. (2000)
found evidence of greater accuracy with MPH, and Elliott et al. (1997) found a trend for the
same. In Mehta et al.’s study, this effect depended on subjects’ working memory ability: the
lower a subject’s score on placebo, the greater the improvement on MPH. In Elliott et al.’s
study, MPH enhanced performance for the group of subjects who received the placebo first
and made little difference for the other group. The reason for this difference is unclear, but
as mentioned above, this may reflect ability differences between the groups. More recently,
Clatworthy et al. (2009) undertook a positron emission tomography (PET) study of MPH
effects on two tasks, one of which was the CANTAB spatial working memory task. They
failed to find consistent effects of MPH on working memory performance but did find a
systematic relation between the performance effect of the drug in each individual and its
effect on individuals’ dopamine activity in the ventral striatum.
Two additional studies used other spatial working memory tasks. Barch and Carter (2005)
required subjects to maintain one of 18 locations on the perimeter of a circle in working
memory and then report the name of the letter that appeared there in a similarly arranged
circle of letters. d-AMP caused a speeding of responses but no change in accuracy. Fleming
et al. (1995) referred to a spatial delay response task, with no further description or citation.
They reported no effect of d-AMP in the task except in the zero-delay condition (which
presumably places minimal demand on working memory).
Finally, Schmedtje et al. (1988) used a delayed matching task in which one random pattern
of filled squares in a 10 × 10 matrix must be held in working memory and compared with
another and judged same or different. No effect was observed with a fairly low dose of dAMP.
In sum, the evidence concerning stimulant effects of working memory is mixed, with some
findings of enhancement and some null results, although no findings of overall performance
impairment. A few studies showed greater enhancement for less able participants, including

Psychol Bull. Author manuscript; available in PMC 2013 March 08.

Smith and Farah

Page 13

two studies reporting overall null results. When significant effects have been found, their
sizes vary from small to large, as shown in Table 4. Taken together, these results suggest
that stimulants probably do enhance working memory, at least for some individuals in some
task contexts, although the effects are not so large or reliable as to be observable in all or
even most working memory studies.
Do Prescription Stimulants Enhance Cognitive Control?
Cognitive control is a broad concept that refers to guidance of cognitive processes in
situations where the most natural, automatic, or available action is not necessarily the correct
one. Such situations typically evoke a strong inclination to respond but require people to
resist responding, or they evoke a strong inclination to carry out one type of action but
require a different type of action. The sources of these inclinations that must be overridden
are various and include overlearning (e.g., the overlearned tendency to read printed words in
the Stroop task), priming by recent practice (e.g., the tendency to respond in the go/no-go
task when the majority of the trials are go trials, or the tendency to continue sorting cards
according to the previously correct dimension in the Wisconsin Card Sorting Test [WCST];
Grant & Berg, 1948) and perceptual salience (e.g., the tendency to respond to the numerous
flanker stimuli as opposed to the single target stimulus in the flanker task). For the sake of
inclusiveness, we also consider the results of studies of reward processing in this section, in
which the response tendency to be overridden comes from the desire to have the reward
immediately.
Table 5 lists the results of 16 tasks from 13 articles on the effects of d-AMP or MPH on
cognitive control. One of the simplest tasks used to study cognitive control is the go/no-go
task. Subjects are instructed to press a button as quickly as possible for one stimulus or class
of stimuli (go) and to refrain from pressing for another stimulus or class of stimuli (no go).
De Wit et al. (2002) used a version of this task to measure the effects of d-AMP on subjects’
ability to inhibit a response and found enhancement in the form of decreased false alarms
(responses to no-go stimuli) and increased speed of correct go responses. They also found
that subjects who made the most errors on placebo experienced the greatest enhancement
from the drug.
The stop-signal task has been used in a number of laboratories to study the effects of
stimulants on cognitive control. In this task, subjects are instructed to respond as quickly as
possible by button press to target stimuli except on certain trials, when the target is followed
by a stop signal. On those trials, they must try to avoid responding. The stop signal can
follow the target stimulus almost immediately, in which case it is fairly easy for subjects to
cancel their response, or it can come later, in which case subjects may fail to inhibit their
response. The main dependent measure for stop-signal task performance is the stop time,
which is the average go reaction time minus the interval between the target and stop signal
at which subjects inhibit 50% of their responses. De Wit and colleagues have published two
studies of the effects of d-AMP on this task. De Wit, Crean, and Richards (2000) reported no
significant effect of the drug on stop time for their subjects overall but a significant effect on
the half of the subjects who were slowest in stopping on the baseline trials. De Wit et al.
(2002) found an overall improvement in stop time in addition to replicating their earlier
finding that this was primarily the result of enhancement for the subjects who were initially
the slowest stoppers. In contrast, Filmore, Kelly, and Martin (2005) used a different measure
of cognitive control in this task, simply the number of failures to stop, and reported no
effects of d-AMP.
The Stroop task tests the ability to inhibit the overlearned process of reading by presenting
color names in colored ink and instructing subjects to either read the word (low need for
cognitive control because this is the habitual response to printed words) or name the ink
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color (high need for cognitive control). Barch and Carter (2005) administered this task to
normal control subjects on placebo and d-AMP and found speeding of responses with the
drug. However, the speeding was roughly equivalent for the conditions with low and high
cognitive control demands, suggesting that the observed facilitation may not have been
specific to cognitive control.
As mentioned earlier, cognitive control is needed not only for inhibiting actions, but also for
shifting from one kind of action or mental set to another. The WCST taxes cognitive control
by requiring the subject to shift from sorting cards by one dimension (e.g., shape) to another
(e.g., color); failures of cognitive control in this task are manifest as perseverative errors in
which subjects continue sorting by the previously successful dimension. Three studies
included the WCST in their investigations of the effects of d-AMP on cognition (Fleming et
al., 1995; Mattay et al., 1996, 2003), and none revealed overall effects of facilitation.
However, Mattay et al. (2003) subdivided their subjects according to COMT genotype and
found differences in both placebo performance and effects of the drug. Subjects who were
homozygous for the val allele (associated with lower prefrontal dopamine activity) made
more perseverative errors on placebo than other subjects and improved significantly with dAMP. Subjects who were homozygous for the met allele performed best on placebo and
made more errors on d-AMP.
The intradimensional– extradimensional shift task from the CANTAB battery was used in
two studies of MPH and measures the ability to shift the response criterion from one
dimension to another, as in the WCST, as well as to measure other abilities, including
reversal learning, measured by performance in the trials following an intradimensional shift.
With an intradimensional shift, the learned association between values of a given stimulus
dimension and reward versus no reward is reversed, and participants must learn to reverse
their responses accordingly. Elliott et al. (1997) reported finding no effects of the drug on
ability to shift among dimensions in the extradimensional shift condition and did not
describe performance on the intradimensional shift. Rogers et al. (1999) found that accuracy
improved but responses slowed with MPH on trials requiring a shift from one dimension to
another, which leaves open the question of whether the drug produced net enhancement,
interference, or neither on these trials once the tradeoff between speed and accuracy is taken
into account. For intradimensional shifts, which require reversal learning, these authors
found drug-induced impairment: significantly slower responding accompanied by a
borderline-significant impairment of accuracy.
Two studies investigated the effects of MPH on reversal learning in simple two-choice tasks
(Clatworthy et al., 2009; Dodds et al., 2008). In these tasks, participants begin by choosing
one of two stimuli and, after repeated trials with these stimuli, learn that one is usually
rewarded and the other is usually not. The rewarded and nonrewarded stimuli are then
reversed, and participants must then learn to choose the new rewarded stimulus. Although
each of these studies found functional neuroimaging correlates of the effects of MPH on
task-related brain activity (increased blood oxygenation level-dependent signal in frontal
and striatal regions associated with task performance found by Dodds et al., 2008, using
fMRI and increased dopamine release in the striatum as measured by increased raclopride
displacement by Clatworthy et al., 2009, using PET), neither found reliable effects on
behavioral performance in these tasks. The one significant result concerning purely
behavioral measures was Clatworthy et al.’s (2009) finding that participants who scored
higher on a self-report personality measure of impulsivity showed more performance
enhancement with MPH. MPH’s effect on performance in individuals was also related to its
effects on individuals’ dopamine activity in specific regions of the caudate nucleus.
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The Trail Making Test is a paper-and-pencil neuropsychological test with two parts, one of
which requires shifting between stimulus categories. Part A simply requires the subject to
connect circled numbers in ascending order. Part B requires the subject to connect circled
numbers and letters in an interleaved ascending order (1, A, 2, B, 3, C….), a task that places
heavier demands on cognitive control. Silber et al. (2006) analyzed the effect of d-AMP on
Trails A and B and failed to find an effect.
The flanker task is designed to tax cognitive control by requiring subjects to respond based
on the identity of a target stimulus (H or S) and not the more numerous and visually salient
stimuli that flank the target (as in a display such as HHHSHHH). Servan-Schreiber, Carter,
Bruno, and Cohen (1998) administered the flanker task to subjects on placebo and d-AMP.
They found an overall speeding of responses but, more importantly, an increase in accuracy
that was disproportionate for the incongruent conditions, that is, the conditions in which the
target and flankers did not match and cognitive control was needed.
Perceptual–motor congruency was the basis of a study by Fitzpatrick et al. (1988) in which
subjects had to press buttons to indicate the location of a target stimulus in a display. In the
simple condition, the left-to-right positions of the buttons are used to indicate the left-toright positions of the stimuli, a natural mapping that requires little cognitive control. In the
rotation condition, the mapping between buttons and stimulus positions is shifted to the right
by one and wrapped around, such that the left-most button is used to indicate the right-most
position. Cognitive control is needed to resist responding with the other, more natural
mapping. MPH was found to speed responses in this task, and the speeding was
disproportionate for the rotation condition, consistent with enhancement of cognitive
control.
Finally, two tasks measuring subjects’ ability to control their responses to monetary rewards
were used by de Wit et al. (2002) to assess the effects of d-AMP. When subjects were
offered the choice between waiting 10 s between button presses for high-probability
rewards, which would ultimately result in more money, and pressing a button immediately
for lower probability rewards, d-AMP did not affect performance. However, when subjects
were offered choices between smaller rewards delivered immediately and larger rewards to
be delivered at later times, the normal preference for immediate rewards was weakened by
d-AMP. That is, subjects were more able to resist the impulse to choose the immediate
reward in favor of the larger reward.
Taken together, the available results are mixed, with slightly more null results than overall
positive findings of enhancement and evidence of impairment in one reversal learning task.
As the effect sizes listed in Table 5 show, the effects when found are generally substantial.
When drug effects were assessed as a function of placebo performance, genotype, or selfreported impulsivity, enhancement was found to be greatest for participants who performed
most poorly on placebo, had a COMT genotype associated with poorer executive function,
or reported being impulsive in their everyday lives. In sum, the effects of stimulants on
cognitive control are not robust, but MPH and d-AMP appear to enhance cognitive control
in some tasks for some people, especially those less likely to perform well on cognitive
control tasks.
Do Prescription Stimulants Enhance Other Executive Functions?
Having reviewed the literature on enhancement of working memory and cognitive control,
we are left with a small set of studies that seem relevant to executive function but do not fit
easily under the previous rubrics and have little else in common with each other.
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As shown in Table 6, two of these are fluency tasks, which require the generation of as large
a set of unique responses as possible that meet the criteria given in the instructions. Fluency
tasks are often considered tests of executive function because they require flexibility and the
avoidance of perseveration and because they are often impaired along with other executive
functions after prefrontal damage. In verbal fluency, subjects are asked to generate as many
words that begin with a specific letter as possible. Neither Fleming et al. (1995), who
administered d-AMP, nor Elliott et al. (1997), who administered MPH, found enhancement
of verbal fluency. However, Elliott et al. found enhancement on a more complex nonverbal
fluency task, the sequence generation task. Subjects were able to touch four squares in more
unique orders with MPH than with placebo.
Raven’s Progressive Matrices (Raven, 1990) are a nonverbal intelligence test that requires
subjects to complete sequences of designs with the appropriate choice from a multiplechoice set. Analogical reasoning is emphasized. Mattay et al. (1996) found that subjects
scored higher on such items after d-AMP than placebo.
Two variants of the Towers of London task were used by Elliott et al. (1997) to study the
effects of MPH on planning. The object of this task is for subjects to move game pieces
from one position to another while adhering to rules that constrain the ways in which they
can move the pieces, thus requiring subjects to plan their moves several steps ahead. Neither
version of the task revealed overall effects of the drug, but one version showed impairment
for the group that received the drug first, and the other version showed enhancement for the
group that received the placebo first.
Kennedy et al. (1990) administered what they termed a grammatical reasoning task to
subjects, in which a sentence describing the order of two letters, A and B, is presented along
with the letter pair, and subjects must determine whether or not the sentence correctly
describes the letter pair. They found no effect of d-AMP on performance of this task.
Schroeder, Mann-Koepke, Gualtieri, Eckerman, and Breese (1987) assessed the performance
of subjects on placebo and MPH in a game that allowed subjects to switch between two
different sectors seeking targets to shoot. They did not observe an effect of the drug on
overall level of performance, but they did find fewer switches between sectors among
subjects who took MPH, and perhaps because of this, these subjects did not develop a
preference for the more fruitful sector.
Only two of the eight experiments reviewed in this section found that stimulants enhanced
performance, on a nonverbal fluency task in one case and in Raven’s Progressive Matrices
in the other. The small number of studies of any given type makes it difficult to draw
general conclusions about the underlying executive function systems that might be
influenced.
Summary Regarding Stimulant Effects on Cognition
The title question, whether prescription stimulants are smart pills, does not find a unanimous
answer in the literature. The preponderance of evidence is consistent with enhanced
consolidation of long-term declarative memory. For executive function, the overall pattern
of evidence is much less clear. Over a third of the findings show no effect on the cognitive
processes of healthy nonelderly adults. Of the rest, most show enhancement, although
impairment has been reported (e.g., Rogers et al., 1999), and certain subsets of participants
may experience impairment (e.g., higher performing participants and/or those homozygous
for the met allele of the COMT gene performed worse on drug than placebo; Mattay et al.,
2000, 2003). Whereas the overall trend is toward enhancement of executive function, the
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literature contains many exceptions to this trend. Furthermore, publication bias may lead to
underreporting of these exceptions.
Null results are generally less likely to be published. Consistent with the operation of such a
bias in the present literature, the null results found in our survey were invariably included in
articles reporting the results of multiple tasks or multiple measures of a single task;
published single-task studies with exclusively behavioral measures all found enhancement.
This suggests that some single-task studies with null results have gone unreported. The
present mixed results are consistent with those of other recent reviews that included data
from normal subjects, using more limited sets of tasks or medications (Advokat, 2010;
Chamberlain et al., 2010; Repantis, Schlattmann, Laisney, & Heuser, 2010).
Interpreting equivocal findings of cognitive enhancement—How should the
mixed results just summarized be interpreted vis-á-vis the cognitive-enhancing potential of
prescription stimulants? One possibility is that d-AMP and MPH enhance cognition,
including the retention of just-acquired information and some or all forms of executive
function, but that the enhancement effect is small. If this were the case, then many of the
published studies were underpowered for detecting enhancement, with most samples sizes
under 50. It follows that the observed effects would be inconsistent, a mix of positive and
null findings.
Brain-imaging studies are consistent with the existence of small effects that are not reliably
captured by the behavioral paradigms of the literature reviewed here. Typically with
executive function tasks, reduced activation of task-relevant areas is associated with better
performance and is interpreted as an indication of higher neural efficiency (e.g., Haier,
Siegel, Tang, Abel, & Buchsbaum, 1992). Several imaging studies showed effects of
stimulants on task-related activation while failing to find effects on cognitive performance.
Although changes in brain activation do not necessarily imply functional cognitive changes,
they are certainly suggestive and may well be more sensitive than behavioral measures.
Evidence of this comes from a study of COMT variation and executive function. Egan and
colleagues (2001) found a genetic effect on executive function in an fMRI study with
sample sizes as small as 11 but did not find behavioral effects in these samples. The genetic
effect on behavior was demonstrated in a separate study with over a hundred participants. In
sum, d-AMP and MPH measurably affect the activation of task-relevant brain regions when
participants’ task performance does not differ. This is consistent with the hypothesis
(although by no means positive proof) that stimulants exert a true cognitive-enhancing effect
that is simply too small to be detected in many studies.
If stimulants truly enhance cognition but do so to only a small degree, this raises the
question of whether small effects are of practical use in the real world. Under some
circumstances, the answer would undoubtedly be yes. Success in academic and occupational
competitions often hinges on the difference between being at the top or merely near the top.
A scholarship or a promotion that can go to only one person will not benefit the runner-up at
all. Hence, even a small edge in the competition can be important.
Another interpretation of the mixed results in the literature is that, in some cases at least,
individual differences in response to stimulants have led to null results when some
participants in the sample are in fact enhanced and others are not. This possibility is not
inconsistent with the previously mentioned ones; both could be at work. Evidence has
already been reviewed that ability level, personality, and COMT genotype modulate the
effect of stimulants, although most studies in the literature have not broken their samples
down along these dimensions. There may well be other as-yet-unexamined individual
characteristics that determine drug response. The equivocal nature of the current literature

Psychol Bull. Author manuscript; available in PMC 2013 March 08.

Smith and Farah

Page 18

may reflect a mixture of substantial cognitive-enhancement effects for some individuals,
diluted by null effects or even counteracted by impairment in others.
An additional complexity, related to individual differences, concerns dosage. This factor,
which varies across studies and may be fixed or determined by participant body weight
within a study, undoubtedly influences the cognitive effects of stimulant drugs. Furthermore,
single-unit recordings with animals and, more recently, imaging of humans indicate that the
effects of stimulant dose are nonmonotonic; increases enhance prefrontal function only up to
a point, with further increases impairing function (e.g., Arnsten, 1998; Mattay et al., 2003;
Robbins & Arnsten, 2009). Yet additional complexity comes from the fact that the optimal
dosage depends on the same kinds of individual characteristics just discussed and on the task
(Mattay et al., 2003).
Taken together, these considerations suggest that the cognitive effects of stimulants for any
individual in any task will vary based on dosage and will not easily be predicted on the basis
of data from other individuals or other tasks. Optimizing the cognitive effects of a stimulant
would therefore require, in effect, a search through a high-dimensional space whose
dimensions are dose; individual characteristics such as genetic, personality, and ability
levels; and task characteristics. The mixed results in the current literature may be due to the
lack of systematic optimization.

Outstanding Issues
Open Questions Concerning the Cognitive Neuroscience of Cognitive Enhancement
Given the size of the literature just reviewed, it is surprising that so many basic questions
remain open. Although d-AMP and MPH appear to enhance retention of recently learned
information and, in at least some individuals, also enhance working memory and cognitive
control, there remains great uncertainty regarding the size and robustness of these effects
and their dependence on dosage, individual differences, and specifics of the task.
In addition, while the laboratory research reviewed here is of interest concerning the effects
of stimulant drugs on specific cognitive processes, it does not tell us about the effects on
cognition in the real world. How do these drugs affect academic performance when used by
students? How do they affect the total knowledge and understanding that students take with
them from a course? How do they affect various aspects of occupational performance?
Similar questions have been addressed in relation to students and workers with ADHD
(Barbaresi, Katusic, Colligan, Weaver, & Jacobsen, 2007; Halmøy, Fasmer, Gillberg, &
Haavik, 2009; see also Advokat, 2010) but have yet to be addressed in the context of
cognitive enhancement of normal individuals.
Another empirical question concerns the effects of stimulants on motivation, which can
affect academic and occupational performance independent of cognitive ability. Volkow and
colleagues (2004) showed that MPH increased participants’ self-rated interest in a relatively
dull mathematical task. This is consistent with student reports that prescription stimulants
make schoolwork seem more interesting (e.g., DeSantis et al., 2008). To what extent are the
motivational effects of prescription stimulants distinct from their cognitive effects, and to
what extent might they be more robust to differences in individual traits, dosage, and task?
Are the motivational effects of stimulants responsible for their usefulness when taken by
normal healthy individuals for cognitive enhancement?
Finally, all of the questions raised here in relation to MPH and d-AMP can also be asked
about newer drugs and even about nonpharmacological methods of cognitive enhancement.
An example of a newer drug with cognitive-enhancing potential is modafinil. Originally
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marketed as a therapy for narcolepsy, it is widely used off label for other purposes (Vastag,
2004), and a limited literature on its cognitive effects suggests some promise as a cognitive
enhancer for normal healthy people (see Minzenberg & Carter, 2008, for a review).
Nondrug cognitive-enhancement methods include the high tech and the low. An example of
the former is transcranial magnetic stimulation (TMS), whereby weak currents are induced
in specific brain areas by magnetic fields generated outside the head. TMS is currently being
explored as a therapeutic modality for neuropsychiatric conditions as diverse as depression
and ADHD and is capable of enhancing the cognition of normal healthy people (e.g.,
Kirschen, Davis-Ratner, Jerde, Schraedley-Desmond, & Desmond, 2006). An older
technique, transcranial direct current stimulation (tDCS), has become the subject of renewed
research interest and has proven capable of enhancing the cognitive performance of normal
healthy individuals in a variety of tasks. For example, Flöel, Rösser, Michka, Knecht, and
Breitenstein (2008) reported enhancement of learning and Dockery, Hueckel-Weng,
Birbaumer, and Plewnia (2009) reported enhancement of planning with tDCS.
Low-tech methods of cognitive enhancement include many components of what has
traditionally been viewed as a healthy lifestyle, such as exercise, good nutrition, adequate
sleep, and stress management. These low-tech methods nevertheless belong in a discussion
of brain enhancement because, in addition to benefiting cognitive performance, their effects
on brain function have been demonstrated (Almeida et al., 2002; Boonstra, Stins,
Daffertshofer, & Beek, 2007; Hillman, Erickson, & Kramer, 2008; Lutz, Slagter, Dunne, &
Davidson, 2008; Van Dongen, Maislin, Mullington, & Dinges, 2003).
Open Questions Concerning the Epidemiology of Cognitive Enhancement
It is known that American college students have embraced cognitive enhancement, and some
information exists about the demographics of the students most likely to practice cognitive
enhancement with prescription stimulants. Outside of this narrow segment of the population,
very little is known. What happens when students graduate and enter the world of work? Do
they continue using prescription stimulants for cognitive enhancement in their first jobs and
beyond? How might the answer to this question depend on occupation? For those who stay
on campus to pursue graduate or professional education, what happens to patterns of use? To
what extent do college graduates who did not use stimulants as students begin to use them
for cognitive enhancement later in their careers? To what extent do workers without college
degrees use stimulants to enhance job performance? How do the answers to these questions
differ for countries outside of North America, where the studies of Table 1 were carried out?
Another important epidemiological question about the use of prescription stimulants for
cognitive enhancement concerns the risk of dependence. MPH and d-AMP both have high
potential for abuse and addiction related to their effects on brain systems involved in
motivation. On the basis of their reanalysis of NSDUH data sets from 2000 to 2002, Kroutil
and colleagues (2006) estimated that almost one in 20 nonmedical users of prescription
ADHD medications meets criteria for dependence or abuse. This sobering estimate is based
on a survey of all nonmedical users. The immediate and long-term risks to individuals
seeking cognitive enhancement remain unknown.
An entirely different set of questions concerns cognitive enhancement in younger students,
including elementary school and even preschool children. Some children can function
adequately in school without stimulants but perform better with them; medicating such
children could be considered a form of cognitive enhancement. How often does this occur?
What are the roles and motives of parents, teachers, and pediatricians in these cases? These
questions have been discussed elsewhere and deserve continued attention (Diller, 1996;
Singh & Keller, 2010).
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Regarding other methods of cognitive enhancement, little systematic research has been done
on their prevalence among healthy people for the purpose of cognitive enhancement. One
exploratory survey found evidence of modafinil use by people seeking cognitive
enhancement (Maher, 2008), and anecdotal reports of this can be found online (e.g.,
Arrington, 2008; Madrigal, 2008). Whereas TMS requires expensive equipment, tDCS can
be implemented with inexpensive and widely available materials, and online chatter
indicates that some are experimenting with this method.

Conclusions
The goal of this article has been to synthesize what is known about the use of prescription
stimulants for cognitive enhancement and what is known about the cognitive effects of these
drugs. We have eschewed discussion of ethical issues in favor of simply trying to get the
facts straight. Although ethical issues cannot be decided on the basis of facts alone, neither
can they be decided without relevant facts. Personal and societal values will dictate whether
success through sheer effort is as good as success with pharmacologic help, whether the
freedom to alter one’s own brain chemistry is more important than the right to compete on a
level playing field at school and work, and how much risk of dependence is too much risk.
Yet these positions cannot be translated into ethical decisions in the real world without
considerable empirical knowledge. Do the drugs actually improve cognition? Under what
circumstances and for whom? Who will be using them and for what purposes? What are the
mental and physical health risks for frequent cognitive-enhancement users? For occasional
users?
The one indisputable finding from the literature so far is that many people are seeking
cognitive enhancement. Beyond that, the literature yields only partial and tentative answers
to the questions just raised. Given the potential impact of cognitive enhancement on society,
more research is needed. For research on the epidemiology of cognitive enhancement,
studies focused on the cognitive-enhancement practices and experiences of students and
nonstudent workers are needed. For research on the cognitive effects of prescription
stimulants, larger samples are needed. Only with substantially larger samples will it be
possible to assess small but potentially important benefits, as well as risks, and to distinguish
individual differences in drug response. Large samples would also be required to compare
these effects to the cognitive effects of improved sleep, exercise, nutrition, and stress
management. To include more ecologically valid measures of cognition in academic and
work environments would in addition require the equivalent of a large clinical trial.
Unfortunately, cognitive enhancement falls between the stools of research funding, which
makes it unlikely that such research programs will be carried out. Disease-oriented funders
will, by definition, not support research on normal healthy individuals. The topic intersects
with drug abuse research only in the assessment of risk, leaving out the study of potential
benefits, as well as the comparative benefits of other enhancement methods. As a
fundamentally applied research question, it will not qualify for support by funders of basic
science. The pharmaceutical industry would be expected to support such research only if
cognitive enhancement were to be considered a legitimate indication by the FDA, which we
hope would happen only after considerably more research has illuminated its risks, benefits,
and societal impact. Even then, industry would have little incentive to delve into all of the
issues raised here, including the comparison of drug effects to nonpharmaceutical means of
enhancing cognition.
The absence of a suitable home for this needed research on the current research funding
landscape exemplifies a more general problem emerging now, as applications of
neuroscience begin to reach out of the clinical setting and into classrooms, offices,
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courtrooms, nurseries, marketplaces, and battlefields (Farah, 2011). Most of the
longstanding sources of public support for neuroscience research are dedicated to basic
research or medical applications. As neuroscience is increasingly applied to solving
problems outside the medical realm, it loses access to public funding. The result is products
and systems reaching the public with less than adequate information about effectiveness
and/or safety. Examples include cognitive enhancement with prescription stimulants, eventrelated potential and fMRI-based lie detection, neuroscience-based educational software,
and anti-brain-aging computer programs. Research and development in nonmedical
neuroscience are now primarily the responsibility of private corporations, which have an
interest in promoting their products. Greater public support of nonmedical neuroscience
research, including methods of cognitive enhancement, will encourage greater knowledge
and transparency concerning the efficacy and safety of these products and will encourage the
development of products based on social value rather than profit value.
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Figure 1.

Flow diagram of epidemiology literature search completed July 1, 2010. Search terms were

nonmedical use, nonmedical use, misuse, or illicit use, and prescription stimulants,
dextroamphetamine, methylphenidate, Ritalin, or Adderall. Stages of subsequent review
used the information contained in the titles, abstracts, and articles to determine whether
articles reported studies of the extent of nonmedical prescription stimulant use by students
and related questions addressed in the present article including students’ motives and
frequency of use.
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Figure 2.

Flow diagram of cognitive neuroscience literature search completed July 2, 2010. Search
terms were dextroamphetamine, Aderrall, methylphenidate, or Ritalin, and cognitive,
cognition, learning, memory, or executive function, and healthy or normal. Stages of
subsequent review used the information contained in the titles, abstracts, and articles to
determine whether articles reported studies meeting the inclusion criteria stated in the text.
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purchased from other students;
1.4% had sold to other students
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10 (all male)
32 (all male)
20 (14 male)
36 (18 male)
20 (14 male)
28 (all male)
22 (10 male)
20 (all male)
17 (9 male)

17 (all male)

Camp-Bruno & Herting (1994)

Clatworthy et al. (2009)

Cooper et al. (2005)

de Wit, Cream, & Richards (2000)

de Wit, Enggasser, & Richards (2002)

Dodds et al. (2008)

Elliott et al. (1997)

Fillmore, Kelly, & Martin (2005)

Fitzpatrick, Klorman, Brumaghim, & Keefover (1988)

Fleming, Bigelow, Weinberger, & Goldberg (1995)

Hurst, Radlow, & Weidner (1968)

10 (8 male)
26 (11 male)

Mattay et al. (2000)

Mattay et al. (2003)

31

22–32

Wisconsin Card Sorting Test, n-back

n-back

Wisconsin Card Sorting Test, Raven’s Progressive Matrices

Motor sequence learning, item recognition

8 (4 male)

Mattay et al. (1996)

21–35

11 (5 male)

Makris, Rush, Frederich, Taylor, & Kelly (2007)

25

Continuous performance test (double and B–X versions)

Item recognition, grammatical reasoning

Associative learning

Verbal learning, associative learning, continuous performance test
(unknown version), Wisconsin Card Sorting Test, spatial working memory,
verbal fluency

Item recognition, stimulus evaluation/response selection task (complex)

Stop-signal task, n-back

Attentional set-shifting, spatial span, spatial working memory, verbal
fluency, Tower of London, new Tower of London

Reversal learning

Verbal learning, stop-signal task, go/no-go, delay discounting, delay of
gratification, digit span

Stop-signal task

Continuous performance test (double version)

Spatial working memory, reversal learning

Verbal learning

Item recognition

Associative learning

Associative learning

Verbal learning

Associative learning

Associative learning

Stroop test, spatial working memory

Tasks

Motor sequence learning

18–45

21–36

21 (median)

18–30

19–33

18–45

21–35

18–25

22–32

19–33

30–40

“university students”

18–26

18–35

20–35

20–33

Range

Age (years)

60 (all male)
1.4

8.2

1.6

3.2

1.8

3.6

2.2

8.7

SD

Kumari et al. (1997)

26.3

27.5

19.7

21.5

21.3

22.2

22.3

23.0

20.9

22.8

36.6

M

Klorman et al. (1984)

8

48 (22 male)

Callaway (1983)

Kennedy, Odenheimer Baltzley, Dunlap, & Wood (1990)

30 (all male)
8 (all female)

Burns, House, Fensch, & Miller (1967)

22 (12 male)

60 (all male)

Breitenstein et al. (2006)
48 (23 male)

40 (all male)

Breitenstein et al. (2004)

Brumaghim & Klorman (1998)

22 (12 male)

Barch & Carter (2005)

Brignell, Rosenthal, & Curran (2007)

Sample N

Study

Overview of the Cognitive Effects Studies
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18 (11 male)
23 (11 male)
31 (all male)
16 (all male)
12 (all male)

Mintzer & Griffiths (2007)

Oken, Kishiyama, & Salinsky (1995)

Rapoport, Buchsbaum, & Weingartner (1980)

Rogers et al. (1999)

Schlösser et al. (2009)

18 (all male)
22 (all male)
18 (13 male)
12 (6 male)
6 (all male)

Soetens, Casaer, D’Hooge, & Hueting (1995)

Soetens, D’Hooge, & Hueting (1993)

Strauss et al. (1984)

Tipper et al. (2005)

Unrug, Coenen, & van Luijtelaar (1997)

Ward, Kelly, Foltin, & Fischman (1997)

54 (all female)
18 (13 male)
36 (all male)

Willet (1962)

M. C. Wilson, Wilman, Bell, Asghar, & Silverstone (2004)

Zeeuws & Soetens (2007)

96

18 (all male)

Silber, Croft, Papafotiou, & Stough (2006)

Weitzner (1965)

10 (5 male)
20 (10 male)

Servan-Schreiber, Carter, Bruno, & Cohen (1998)

15 (all male)

Schroeder,Mann-Koepke, Gualtieri, Eckerman, & Breese (1987)

8

10 (all male)

Mehta et al. (2000)

Schmedtje, Oman, Letz, & Baker (1988)

Sample N

Study

25.4

26.1

29.7

24

24

19.2

25.4

26.8

20.4

25

23

34.8

M

6.5

0.87

3.2

2.1

0.4

3.4

SD

18–25

27–35

19–27

19–25

24–39

18–40

24–32

“college-age”

21–39

18–39

Range

Age (years)

Verbal learning

Item recognition

Verbal learning

Associative learning

Motor sequence learning, item recognition

Verbal learning

Item recognition

Paired-associates learning, continuous performance test (double version)

Verbal learning

Verbal learning

Digit span, Trail Making Test

Flanker task

Strategic choice task

Digit span, pattern memory

Associative learning

Attentional set-shifting

Verbal learning

Digit span

Verbal learning, item recognition, n-back

Spatial working memory

Tasks
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Motor sequence learning

Probabilistic learning

Location of stimulus and response

Word pairs

Associative learning

14 mg/70 kg
20 mg
14 mg/70kg

d-AMP
MPH
d-AMP

40 mg

MPH
5 mg

0.25 mg/kg

d-AMP

d-AMP

0.25 mg/kg

d-AMP

15 mg

0.25 mg/kg

d-AMP

d-AMP

0.3 mg/kg

MPH

10 mg

20 mg

MPH

10, 20mg

10 mg

d-AMP

d-AMP

10 mg

d-AMP

d-AMP

0.25 mg/kg, 0.5 mg/kg

d-AMP

20 mg

20 mg/70 kg, 30 mg/70
kg

d-AMP

MPH

0.25 mg/kg

d-AMP

Repeated-exposure verbal learning

20 mg

MPH

Single-exposure verbal learning

Dose
40 mg

Drug
MPH

Task

Memory and Learning

Burns, House, Fensch, & Miller (1967)

No effect

No effect

Steeper learning curve (increase in hits and decrease in misses across
learning sessions)

Kumari et al. (1997)

Schlösser et al. (2009)

Breitenstein et al. (2006)

Breitenstein et al. (2004)

Slower rate of learning (borderline effect; d = 1.46)
Steeper increase in hits and decrease in misses across learning sessions
(d = 0.93); increase in retention after more than 1 year (d = 1.16)

Weitzner (1965)

Strauss et al. (1984)

Hurst, Radlow, & Weidner (1968)

Fleming, Bigelow, Weinberger, & Goldberg
(1995)

Brumaghim & Klorman (1998)

Improved performance only when pairs were uniquely semantically
related (d = 0.41)

No effect

Increase in retention after 1-week delay

No effect

No effect

de Wit, Enggasser, & Richards (2002)
Willett (1962)

Decrease in number of trials to reach criterion (d = 0.23)

Camp-Bruno & Herting (1994)

25 min: no effect

1 hr: no effect; 2 hr: borderline effect

Zeeuws & Soetens (2007)

30 min: no effect; 1 hr through 1 day: improved long-term retention (d
= 0.59–0.66)b

Soetens, D’Hooge, & Hueting (1993)

20 min: no effect; 1 hr through 3 days: improved long-term retention (d
= 0.99)

Unrug, Coenen, & van Luijtelaar (1997)

Soetens, Casaer, D’Hooge, & Hueting (1995)

1 hr through 1 week: improved long-term retention in free recall (d =
0.99–1.03)b; 1 week: improved recognition (d = 1.35)

20 min: no effect

Rapoport, Buchsbaum, &Weingartner (1980)

Mintzer & Griffiths (2007)

2 hr: improved recognition d′ (sensitivity)a; no effect on recall
10 min: improved recall

Fleming, Bigelow, Weinberger, & Goldberg
(1995)

Camp-Bruno & Herting (1994)

Brignell, Rosenthal, & Curran (2007)

Study

20 min: no effect

Up to 2.5 hr: no effect

1 week: improved recognition

Summary of findings

Table 3
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Dose
5, 10 mg
0.035 mg/kg, 0.07 mg/
kg, 0.14 mg/kg

Drug
d-AMP
d-AMP

Multiple effect sizes within this range.

b

Dose effect.

a

Note. d-AMP = dextroamphetamine; MPH = methylphenidate.

Task

No effect

No effect

Summary of findings

Makris, Rush, Frederich, Taylor, & Kelly
(2007)

Ward, Kelly, Foltin, & Fischman (1997)

Study
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10 mg
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Psychol Bull. Author manuscript; available in PMC 2013 March 08.

Digit span

Continuous performance test (B–X
version)

n-back

Continuous performance test (double
version)

0.3 mg/kg

MPH

5 mg
0.42 mg/kg

d-AMP

No effect

Silber, Croft, Papafotiou, & Stough (2006)

Schmedtje, Oman, Letz, & Baker (1988)

Oken, Kishiyama, & Salinsky (1995)

No effect

0.2 mg/kg

MPH
d-AMP

No effect

de Wit, Crean, & Richards (2002)

Increase in performancec

d-AMP

10, 20 mg

Rapoport, Buchsbaum, & Weingartner (1980)
Klorman et al. (1984)

Mintzer & Griffiths (2007)

Mattay et al. (2003)

No effecta

Decrease in errors of omissionc

Mattay et al. (2000)

No effecta

No effect

Fillmore, Kelly, & Martin (2005)

Strauss et al. (1984)

45 min: decrease in reaction time (d = 1.12); 45 min:
decrease in errors of omission (d = 1.25)
Increase in processing ratec

Klorman et al. (1984)

Fleming, Bigelow, Weinberger, & Goldberg
(1995)

5 min: decrease in reaction time (d = 0.12– 0.8)d
45 min: decrease in reaction time; 12.5/45 min:
decrease in errors of omission

Cooper et al. (2005)

5 min: decrease in reaction time; 5 min: decrease in
errors of omissionc

45 min: decrease in reaction time; 45 min: decrease in
errors of omission

20 mg

MPH

20 mg/70 kg, 30 mg/70 kg

d-AMP
0.25 mg/kg, 0.5 mg/kg

0.25 mg/kg

d-AMP

d-AMP

0.25 mg/kg

20 mg

MPH

d-AMP

20 mg

MPH

7.5mg/70 kg, 15 mg/70 kg

0.25 mg/kg

d-AMP

d-AMP

5, 15, 45 mg

MPH

M. C. Wilson, Wilman, Bell, Asghar, &
Silverstone (2004)

Decrease in reaction time (d = 0.68–0.8)d

25 mg

d-AMP

Ward, Kelly, Foltin, & Fischman (1997)

5, 10 mg

d-AMP

Mintzer & Griffiths (2007)

Decrease in reaction time (d = 0.77–1.2)d

2.5, 5.0, 12.5 mg

Tipper et al. (2005)

No effect

20mg/70kg, 30mg/70kg

d-AMP
d-AMP

Makris, Rush, Frederich, Taylor, & Kelly (2007)

Kennedy, Odenheimer, Baltzley, Dunlap, &
Wood (1990)

No effect

Proportion correct sustained across multiple trialsc

No effect

Fitzpatrick, Klorman, Brumaghim, & Keefover
(1988)

Decrease in reaction time (d = 1.06)

Study
Callaway (1983)

Summary of findings
No effect

0.035 mg/kg, 0.07 mg/kg, 0.14 mg/kg

d-AMP

5, 10, 20 mg

Dose

Drug
MPH

Task

Item recognition

Executive Functions: Working Memory

Table 4
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20, 40 mg
0.25 mg/kg
40 mg

MPH
d-AMP
MPH
5 mg

Multiple effect sizes within this range.

Dose effect.

Session Order = Drug interaction.

d

c

b

Individual differences.

a

Note. d-AMP = dextroamphetamine; MPH = methylphenidate.

d-AMP

60 mg

MPH

Pattern memory

0.25 mg/kg

d-AMP

Spatial working memory

20, 40 mg

MPH

Spatial span

Dose

Drug

Task

Elliott et al. (1997)

Decrease in errorsb

No effect

Schmedtje, Oman, Letz, & Baker (1988)

Mehta et al. (2000)

Clatworthy et al. (2009)

No effecta

Decrease in between-search errorsa (d = 0.39)

Barch & Carter (2005)

Decrease in reaction time (d = 0.78)

Fleming, Bigelow, Weinberger, & Goldberg
(1995)

Elliott et al. (1997)

Decrease in errorsb

No effect

Study

Summary of findings
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MPH
d-AMP
d-AMP

Stimulus evaluation/response selection
task (complex)

Delay discounting

Delay of gratification

10, 20 mg

10, 20 mg

0.3 mg/kg

0.25 mg/kg

Dose effect.

Multiple effect sizes within this range.

c

b

Individual differences.

a

Note. d-AMP = dextroamphetamine; MPH = methylphenidate.

d-AMP

Flanker test

0.42 mg/kg

60 mg

MPH
d-AMP

60 mg

MPH

40 mg

Trail Making Test

Reversal learning

20, 40 mg

MPH

0.25 mg/kg

d-AMP
MPH

0.25 mg/kg

d-AMP

Attentional set-shifting

0.25 mg/kg

d-AMP

Wisconsin Card Sorting Test

0.25 mg/kg

7.5mg/70 kg, 15 mg/70
kg

d-AMP
d-AMP

10, 20 mg

d-AMP

Stroop test

10, 20 mg

d-AMP

Stop-signal task

10, 20 mg

Dose

d-AMP

Go/no-go

Drug

Executive Functions: Cognitive Control

Fitzpatrick, Klorman, Brumaghim, & Keefover (1988)
de Wit, Enggasser, & Richards (2002)

Decrease in response time (d = 1.06)
Decrease in delay discounting (k value)b

de Wit, Enggasser, & Richards (2002)

Servan-Schreiber, Carter, Bruno, & Cohen (1998)

Decrease in response time (d = 3.4–4.47)c; increase in
accuracy (incompatible trials) (d = 0.74)

No effect

Silber, Croft, Papafotiou, & Stough (2006)

Clatworthy et al. (2009)

No effecta
No effect

Dodds et al. (2008)

Rogers et al. (1999)

No effect

Elliott et al. (1997)

Increase in intradimensional shift errors (d = 0.66); decrease in
extradimensional shift errors (d = 0.64); increase in response
latencies (d = 0.99– 1.21)c

Mattay et al. (2003)

No effecta
No effect

Mattay et al. (1996)

Fleming, Bigelow, Weinberger, & Goldberg (1995)

No effect

No effect

Barch & Carter (2005)

de Wit, Enggasser, & Richards (2002)

Decrease in stop reaction timea

Decrease in response time (d = 0.98)

de Wit (2000)

No effecta

Fillmore, Kelly, & Martin (2005)

de Wit, Enggasser, & Richards (2002)

Decrease in number of false alarmsa

No effect

Study

Summary of findings
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Table 6

Executive Functions: Other
Task

Drug

Dose

Summary of findings

Study

Verbal fluency

MPH

20, 40 mg

No effect

Elliott et al. (1997)

d-AMP

0.25 mg/kg

No effect

Fleming, Bigelow, Weinberger, &
Goldberg (1995)

Sequence generation

MPH

20, 40 mg

Increase in number of sequences
generateda

Elliott et al. (1997)

Raven’s Progressive Matrices

d-AMP

0.25 mg/kg

Increase in percent of correct responses
(d = 1.08)

Mattay et al. (1996)

Tower of London

MPH

20, 40 mg

Relative decrease in accuracya;
decrease in planning latencya

Elliott et al. (1997)

New Tower of London

MPH

20, 40 mg

Increase in accuracya

Elliott et al. (1997)

Grammatical reasoning

d-AMP

10 mg

No effect

Kennedy, Odenheimer, Baltzley,
Dunlap, & Wood (1990)

Strategic choice task

MPH

0.15 mg/kg, 0.30
mg/kg

Decrease in changeover rate

Schroeder, Mann-Koepke,
Gualtieri, Eckerman, & Breese
(1987)

Note. d-AMP = dextroamphetamine; MPH = methylphenidate.
a

Session Order × Drug interaction.
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